PET Imaging of Multiple Myeloma with 68Ga-NB381
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study uses a special PET scan to look for multiple myeloma in your body. It may help doctors see where the disease is and how active it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 89 years old
- You either have confirmed multiple myeloma, or you are suspected of having it and will have a bone marrow or tissue biopsy within 3 months
- You are not pregnant
- You can understand the study procedures and follow instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan that uses a radioactive tracer (68Ga-BCMA) to find active multiple myeloma cells in your body. It may help doctors better detect and monitor the disease.
This trial compares a new type of PET/MR scan (using a radioactive tracer called Ga-68 PentixaFor) with standard imaging to see if it can better detect multiple myeloma at diagnosis and during follow-up. It may help improve staging and treatment planning.
This trial compares two types of PET/CT scans to see which one better finds lesions (areas of disease) in people with newly diagnosed multiple myeloma. If you qualify, you may help doctors choose the most useful scan to guide care.
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This study tests a new imaging agent called 64Cu-LLP2A to see if it can better detect certain blood cancers like multiple myeloma and low-grade lymphomas. It aims to find tumors more clearly than standard scans, which could help your doctor plan the best care for you.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.